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Abstract 
Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median 
survival of only 15 months in clinical trial populations. However, survival varies greatly 
among patients. As part of central pathology review we addressed the question if 
patients with GBM displaying distinct morphologic features respond differently to 
combined chemo-radiotherapy with temozolomide. Morphologic features were 
systematically recorded for 360 cases with particular focus on presence of an 
oligodendroglioma-like component, and respective correlations with outcome, and 
relevant molecular markers. GBM with an oligodendroglioma-like component (GBM-O) 
represented 15% of all confirmed GBM (52/339) and was not associated with a more 
favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, 
significantly enriched for IDH1 mutations (19% versus 3%, p=0.003) and EGFR 
amplifications (71% versus 48%, p=0.04) compared with other GBM, while co-deletion of 
1p/19q was found in only one case, and the MGMT methylation frequency was alike 
(47% versus 46%). Expression profiles classified most of the GBM-O into two subtypes, 
36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-
palisading necrosis (PPN) was associated with benefit from chemotherapy (p=0.0002), 
while no such effect was present in the absence of PPN (p=0.86). In the adjusted 
interaction model including clinical prognostic factors and MGMT status PPN was 
borderline non-significant (p=0.063). Taken together, recognition of an 
oligodendroglioma-like component in an otherwise classic GBM identifies a 
pathogenetically mixed group without prognostic significance. However, the presence of 
PPN may indicate biological features of clinical relevance for further improvement of 
therapy. 
 
Key words 
glioblastoma – glioblastoma with oligodendroglioma-like component – MGMT – IDH1 – 
EGFR - pathology – temozolomide – randomized trial – pseudopalisading necrosis – 
prognostic factors 
4 
 
Introduction 
 
The introduction of combined chemo-radiotherapy adding temozolomide concomitant 
and adjuvant to radiotherapy has modestly increased outcome of patients with newly 
diagnosed glioblastoma (GBM) [32] in particular in patients whose tumors contain an 
epigenetically inactivated MGMT gene [11]. However, outcome varies dramatically even 
in a homogenously treated patient population with a median survival of 15 months, 2- 
and 5-year survival rates of 27 and 11%, respectively [7,19,21,32]. Histopathologically 
GBM is a heterogeneous tumor type and distinct morphologic subtypes may benefit 
differently from combined chemo-radiotherapy. Furthermore, unequivocal separation of 
GBM and anaplastic astrocytomas from anaplastic oligo-astrocytic neoplasms is difficult. 
Previous reports suggested that distinct morphologic features present in GBM may have 
prognostic value, such as the presence of an oligodendroglioma-like component that 
was associated with better outcome in some studies, while the presence of necrosis has 
been reported as a negative prognostic factor [9,12,16,18,37]. 
Here we addressed the question whether particular morphologic features in GBM 
can identify clinically meaningful subgroups in this patient cohort treated homogenously 
with combined radio-chemotherapy that has become the standard of care. A specific 
goal was to investigate the clinical relevance of recognition of an oligodendroglioma-like 
component in GBM in tumors that had been diagnosed as GBM (all subtypes) by the 
initial local pathology assessment. The histopathological study was carried out as part of 
the central review performed in the phase III EORTC_26981-22981-NCIC_CE.3 trial for 
newly diagnosed GBM [32,33]. The results of this detailed histopathological review were 
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correlated with outcome and benefit from the new concomitant chemo-radiotherapy and 
in a subset of cases associated with genetic information including the MGMT 
methylation status, copy number aberrations (CNAs) of EGFR, CDK4 and MDM2, 
combined loss of chromosomes 1p and 19q, and mutations of IDH1. 
 
Patients and Methods 
Patients 
Patients were enrolled in the phase III EORTC_26981-22981-NCIC_CE.3 trial [33] 
(ClinicalTrials.gov, number NCT00006353) between August 2000 and March 2002. 
Eligibility criteria have been detailed elsewhere [32] and comprised age between 18 and 
70 years, histologically proven newly diagnosed GBM (WHO grade IV), and a WHO 
performance status of 0–2. Patients were randomized to either standard focal 
radiotherapy (RT) with a total dose of 60 Gy or concomitant chemotherapy of oral 
temozolomide (TMZ) at a daily dose of 75 mg/m² given 7 days per week during 
radiotherapy, followed by up to six cycles of adjuvant TMZ (150–200 mg/m²) for 5 days 
every 28 days. All patients had given written informed consent prior to entering the 
study, including for molecular analysis of their tumors. The study was approved by the 
local ethics committees.  
 
Pathology review 
Central review was performed jointly by three experienced neuropathologists (RCJ, KM, 
PW) according to WHO 2000 criteria [15] using a multiheaded microscope. H&E-stained 
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full sections were used for the evaluation. In most cases GFAP-, MIB-1- and a reticulin 
silver stain were available (collectively performed in Lausanne). Morphologic features 
were systematically recorded in a semi-quantitative manner and comprised cellular 
differentiation patterns, types of necrosis (large ischemic type vs. pseudopalisading 
necrosis), microvascular proliferation, and MIB-1 labeling index (see evaluation form, 
Supplementary Figure S1). In line with the WHO classification pseudopalisading 
necrosis (PPN) was defined as irregular, often serpiginous foci of necrosis surrounded 
by densely packed, radially oriented tumor cells. The agreement between the three 
pathologists was recorded. For this study, GBM with an oligodendroglioma-like 
component (GBM-O) were defined according to the following histopathological criteria: 
presence of at least 1 of 2 “major criteria” – ‘diffuse highly cellular and monotonous 
growth at low power magnification’, ‘monomorphous cell population’; and at least 2 of 3 
“minor criteria” - ‘perinuclear halo-formation in tumor cells’, ‘rounded tumor cell nuclei 
with dense chromatin pattern’, ‘chickenwire architecture of tumor microvasculature’. The 
extent of these features in the viable tumor tissue was recorded (<25%, 25-75%, >75%). 
GBM with >25% of the tumor tissue showing oligodendroglioma-like component were 
subclassified as GBM-O (see Fig. 1 for some examples).  
 
Tissue Micro Array, Immunohistochemistry and Molecular Analysis  
Immunohistochemistry for GFAP and MIB-1, and histochemical reticulin staining were 
performed according to standard procedures on whole sections. A tissue micro array 
(TMA) was constructed comprising 130 patient samples where tumor blocks with 
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sufficient tissue were available as reported previously [21]. The TMA was used to screen 
for the most common IDH1 mutation (R132H) using the specific antibody mIDH1R132H 
(clone H14) [4] and for copy number aberrations (CNAs) of selected genes by FISH. 
FISH for EGFR was performed as described [34]. Two-color FISH assay was performed 
using a mixed 1p36/1q25 and 19p13/19q13 dual color probe set (Cat. No 32-231004, 
Vysis, Inc., Applied Biosystems, Downers Grove, IL) as described [31]. Samples 
showing sufficient FISH efficiency (~90% nuclei with signals) were evaluated. If possible, 
signals were scored in at least 200 non-overlapping, intact nuclei. Deletions of 1p and 
19q were scored when at least 50% of tumor nuclei contained one signal. The following 
probes were used for CDK4 and MDM2: KBI-10725 CD4K/SE12 (12q14); KBI-10717 
MDM2/SE12 (12q15) (Kreatech Diagnostics, Amsterdam; NL).  
The MGMT methylation status was determined and reported previously [11,32]. 
Expression of the EGFRvIII mutant, array comparative genomic hybridization (aCGH) 
data, and gene expression data was available for a subgroup of patients [17,21]. 
Additional EGFR amplification data was obtained by quantitative PCR as described [10]. 
Mutation analysis for IDH1 and IDH2 encompassing codon 132 and 172, respectively, 
was performed by direct Sanger sequencing. 
 
Statistics 
The Fishers’ exact test (for binary or nominal categorical data) and the Wilcoxon rank 
sum test (for continuous or ordinal categorical data) were used in the comparisons of 
patient and disease characteristics between subgroups. Survival analyses were 
performed with Kaplan Meier technique with log-rank statistics. The Cox Regression was 
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used for multivariate analyses. All Cox models were fit with age (≤50, 51-60, >60), 
extent of surgery (total, partial, biopsy only), performance status (0, 1, 2), Mini Mental 
Score Examination (<27, 27-30) and MGMT methylation status (unmethylated, 
methylated). Pathological features significant at a 5% level in univariate analyses were 
included in the multivariate model. A treatment effect was assessed using Peto’s 
heterogeneity test (predictive value). No adjustment for multiple testing was performed in 
these exploratory analyses. SAS version 9.2 was used for statistical analyses. 
 
Results 
Histological Diagnosis and Subclassification.  
Central review comprised histological analysis of 360 of 573 patients enrolled (central 
review of Canadian patients was performed independently). Baseline characteristics 
have been published previously [32] and sub-cohort patient characteristics are 
summarized in Supplemental Table S1. Overall the patient characteristics of this subset 
did not differ significantly from the overall study population, other than molecular 
markers that could be determined in patients who had undergone tumor resection in 
contrast to biopsy only. From the total of 360 cases reviewed 6 were considered 
undiagnosable due to insufficient tissue or quality of the sections. Fifteen (4.2%) tumors 
did not fulfill the criteria for GBM and comprised 4 anaplastic astrocytomas (WHO grade 
III; AA), 4 anaplastic oligoastrocytomas (WHO grade III, AOA), 1 anaplastic 
oligodendroglioma (WHO grade III; AO), 2 anaplastic ependymomas (WHO grade III), 2 
pilocytic astrocytomas with malignant changes, 1 low grade glioma (WHO grade II), and 
1 meningioma. Of the non-GBM tumors, 6 were in the RT and 9 in the RT/TMZ arm. The 
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remaining 339 were diagnosed as GBM, of which 3 were subtyped as gliosarcoma and 6 
as giant cell GBM. There was a 95% (338/354) consensus with regard to diagnosis of 
GBM versus non-GBM amongst the three neuropathologists. The median age of 
patients with confirmed GBM was 56 years of age (range 19-79) (Supplemental Table 
S2). 
 
Frequency of GBM with an oligodendroglioma-like component  
The criteria for GBM-O were met in 52 (15%) samples, an expected frequency 
[12,29,37]. Sub-typing of centrally confirmed GBM, including GBM-O, resulted in a 2:1 
agreement for 24 cases, of which 16 overlapped with the debated cases for GBM versus 
non-GBM. In the group classified as GBM-O 2 of 5 were considered as AOA and 2 as 
AO, by one of the neuropathologists. The median age of patients with GBM-O was lower 
than that of the other GBM patients (53y vs 56y, p=0.02) (Supplemental Table S2).  
 
GBM-O encompass a pathogenetically heterogeneous group 
Evaluation of important prognostic molecular markers revealed the same frequency of 
MGMT methylation in GBM-O (47%, 16/34) versus the remaining GBM (46%, 60/131) 
(Table 2). Furthermore, combined loss of 1p/19q, a hallmark of oligodendroglial tumors 
and associated with better prognosis in anaplastic glioma [35], was a rare event, 
observed in a single GBM-O, confirmed by aCGH, and one GBM (Fig. 2, Table 2).  
 Next we investigated if GBM-O exhibit a particular pathogenetic make-up. 
Mutations of the IDH1 gene that are associated with better outcome in GBM [40] were 
significantly enriched in GBM-O (6/32, 19%) as compared to the remaining GBM (3/98, 
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3%; p=0.002). Similarly, EGFR amplification that has been associated with older age 
and potentially worse outcome, was present in 71% of GBM-O (22/31) and 48% of the 
remaining GBM (48/100) (p=0.03). IDH1 and EGFR alterations were mutually exclusive 
as reported before [40]. Intriguingly, of 31 GBM-O for which this genetic information was 
available, 6 carried the IDH1R132H mutation, 22 displayed an EGFR amplification, and 
only three had neither alteration. The presence of an IDH1 or IDH2 hot-spot mutation 
other than IDH1R132H was excluded by direct sequencing in these 3 cases. The notion 
that the GBM-O phenotype identifies at least two pathogenetically distinct subgroups is 
further supported by classification according to the four gene expression based subtypes 
proposed by Verhaak et al. [36]. Of 14 evaluable GBM-O 5 grouped with the proneural, 
6 with the classical, 2 with the mesenchymal, and 1 with the neural GBM-subtypes. In 
accordance with the reported mutation pattern of the 4 subgroups, all GBM with an IDH1 
mutation were in the proneural group, while most EGFR amplified and EGFRvIII positive 
GBM were in the classical subgroup (Fig. 3).  
 
Survival of patients with GBM-O is not different from those with GBM 
Patients with non-GBM pathology (15/354, 4%) were enriched in the patient group with 
overall survival (OS) exceeding 24 months (9/64, 14%), as compared to the short 
survival group (≤9 months, 1/101), and the intermediate group (5/189, 3%) (p<0.001, 
chi-square-test) (Fig. 1). Subsequently, only patients with confirmed GBM (n=339) are 
included for further analysis of morphologic features and outcome. There was no 
difference in OS between GBM and GBM-O (logrank test, p=0.48). Stratification by age 
(≤50, 51-60 or >60) (p=0.55) or MGMT methylation status (p=0.27) did not differentiate 
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survival in the two subgroups. When analyzing the GBM-O separately per randomized 
treatment arm, survival was not different for GBM-O in either arm (TMZ/RT→TMZ arm, 
p=0.81; RT-only arm, p=0.14) (Fig. 4). The respective values for progression-free 
survival were similar (p=0.97, TMZ/RT→TMZ; p=0.2, RT). Likewise, using less strict 
criteria, just presence of any oligodendroglioma-like component, did not show any 
association with outcome in either of the two treatment arms (Table 1). The apparent 
enrichment of patients with presence of any oligodendroglioma-like component in the 
long survivor group as visualized in Figure 2 is due to inclusion of patients where GBM 
was not confirmed.  
 
Associations of histopathological features with tumor genetics 
The MIB-1 labeling index was significantly higher in MGMT methylated GBM with a 
mean index of 38% (n=69) as compared to 30% in MGMT unmethylated tumors (n=84) 
(p=0.0015). A trend for a higher MIB-1 labeling index was associated with IDH1 
mutations and EGFR amplifications (p=0.07, p=0.09). No significant association was 
observed between any morphologic feature and the MGMT methylation status. 
 
Associations of tumor genetics and outcome 
None of the genetic alterations investigated here was associated with a prognostic or a 
predictive value with the exception of MGMT methylation as previously reported 
(Supplementary Table S5) [32,38]. Mutations of IDH1 were rare in confirmed GBM 
(9/130; 7%, for which this information was available) as expected [25] and similarly 
distributed between the treatment arms (5, RT; 4, RT&TMZ), with 5 of 8 assessable 
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cases being MGMT methylated. These small numbers do not allow appropriate 
assessment of the prognostic value of IDH1 mutations (p=0.7, Supplementary Fig. S2). 
The patterns of genetic alterations and outcome are displayed in Figure 1.  
 
Presence of pseudopalisading necroses (PPN) is associated with a treatment 
effect of TMZ 
Correlation of the distinct morphologic features assessed, such as type of necrosis, 
vascular pattern, and cell differentiation, and including the MIB-1 (Ki67) labeling index 
(Supplementary Fig. S1), identified PPN as the only morphologic feature associated with 
outcome (Table 1). PPN was present in 63% of all GBM (212/339) and associated with a 
treatment effect (Fig. 5, Table 1). Addition of TMZ to RT was beneficial in the patient 
cohort exhibiting PPN (p=0.0002), while no such effect was present in the absence of 
PPN (p=0.86) (Fig. 5a). Peto’s interaction test was significant (p=0.026, Fig. 5b), and 
borderline non significant in a Cox interaction model adjusted for known clinical 
prognostic factors (p=0.087, Supplemental Table S3) not accounting for MGMT that was 
available only for a subset of 165 mostly resected tumors (Supplementary Table S1). 
This suggests that indeed PPN may identify a subgroup of chemo-sensitive GBM. The 
incidence of PPN was lower in patients with biopsy only (46% vs 65.4%, p=0.01), while 
no association with age was observed (p=0.15). To exclude a bias of potential 
underestimation of PPN in stereotactic biopsies resulting from the small sample size, 
and the fact that biopsy only by itself is an unfavourable prognostic factor, the analyses 
were repeated in patients who underwent a tumor resection. Peto’s test was significant 
(p=0.040, Supplementary Fig. S3) and the adjusted Cox interaction model including 
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MGMT was borderline non significant (p=0.063, Supplementary Table S4). A similar 
treatment effect of PPN was observed for PFS (p<0.0001) in the TMZ-arm, while there 
was a trend in the RT arm (p= 0.078).  
 
Discussion 
The present study was performed to assess prognostic significance of morphological 
features of GBM in the registration trial for temozolomide, with a focus on GBM-O. 
Classification of GBM was in high concordance (>95%) between the 59 centers and 
central review. Expectedly, reclassification as a non-GBM histology was significantly 
enriched among long-term survivors (Fig. 2). The trial analyses and respective reports 
were on an intention-to-treat basis [32], hence include the patients with non-GBM 
histology. 
Identification of unambiguous morphologic features with a prognostic or predictive 
value within GBM would be clinically valuable as such markers could be easily 
implemented in routine histopathologic diagnostics. The recognized phenotypical GBM 
variants, giant cell GBM and gliosarcoma are rare (6, <2% and 3, <1% in this study) [15] 
precluding reliable assessment of a potential prognostic significance when patients are 
treated with the current standard of care. Evaluation of the prognostic value of an 
oligodendroglioma-like component in an otherwise classic GBM revealed no association 
with a more favorable disease course in either of the two treatment arms, in contrast to 
previous studies on GBM-O [9,12,16,18,29]. This discrepancy might be explained by the 
fact that most studies were performed in the pre-TMZ chemotherapy era. GBM-O, as 
defined in this report, seem to benefit similarly from chemoradiotherapy, in line with the 
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identical MGMT methylation frequency compared to other GBM that differs from 
frequencies reported for AO and AOA of over 70% [5,20,27,39]. Further, the delineation 
of “pure” GBM versus GBM-O, AOA and AO is difficult, reflected in variable frequencies 
of reported 1p/19q co-deletions in these studies ranging from 0 to over 20% for the 
GBM-O sub-group [9,12,13,16,18,29].  
This study uncovered that GBM-O encompasses at least two distinct patho-
genetic subgroups, characterized either by EGFR amplifications or IDH1 mutations, and 
further supported by respective expression-based classification (Fig. 3). GBM-O, as 
defined here may in part overlap with the small cell variant of GBM with high cellularity, 
diffuse more or less monotonous growth and relatively small, partly rounded nuclei that 
is known for increased EGFR amplification frequencies [12,18]. Conversely, GBM with 
IDH mutations are now recognized as a distinct subtype with a different 
pathogenetic/epigenetic origin, evolving from lower grade glioma with high frequencies 
of IDH mutations, characteristic for secondary GBM [1,23,40]. Interestingly, IDH mutant 
gliomas are associated with a DNA hypermethylation phenotype [24]. This association 
has recently also been reported in leukemia, identifying a new prognostic subtype, and 
mechanistically linking aberrant metabolism (onco-metabolite) with epigenetic 
deregulation [6,26]. Our finding that recognition of an oligodendroglioma-like phenotype 
in otherwise classic GBM associates two completely different genetic/epigenetic GBM 
subtypes was a surprise and questions the clinical utility of morphologic identification of 
GBM-O. The introduction in the 2007 WHO classification of high-grade malignant 
oligoastrocytic tumors with necrosis as GBM-O [14] has led to substantial controversy 
among pathologists [30], and will certainly have to be re-visited given the recently 
discovered distinct patho-genetic/epigenetic evolution. Determination of oncogenetic 
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events such as IDH status and 1p/19q co-deletions provide a more promising tool for 
robust and reproducible (sub)classification of malignant gliomas [8].  
 
Evaluation of distinct morphologic features in this homogenously treated patient 
population identified PPN as potentially associated with benefit from combined chemo-
radiotherapy. Presence of PPN may reflect the tumor milieu including the tumor 
vascularisation type which may have an effect on drug perfusion and thereby on 
response to chemotherapy. Pseudopalisades are enriched for hypoxic and apoptotic 
tumor cells, with a lower relative proliferation index, and are frequently associated with a 
central degenerating or thrombosed vascular lumen [2,28]. Tumor-associated vascular 
injury has been associated with factors released from glioma cells after genetic 
alterations such as EGFR amplifications, or cellular stress conditions such as hypoxia 
[3,28]. Based on comprehensive analysis of PPN in human GBM and experimental 
models, it has been hypothesized that pseudopalisades comprise hypoxic tumor cells 
migrating away from dysfunctional vessels [2,28]. However, the presence of PPN does 
not directly correlate with hypoxia as suggested by gene expression profiles available for 
50 patients of this cohort [21,22]. No correlation was observed with the previously 
identified hypoxia-induced gene expression signature, while the EGFR expression 
signature (G25) was significantly associated with presence of PPN (p=0.02). Evaluation 
of associations of PPN with previously identified expression signatures in appropriately 
powered studies may indicate underlying molecular mechanisms that merit further 
analysis for improvement of therapy. Respective hypotheses may be tested in the 
database of ‘The Cancer Genome Atlas’ (TCGA) once the morphologic information will 
become publically available [36]. In contrast to our study, Homma et al. [12] reported an 
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association of presence of any type of necrosis with worse outcome. This discrepancy 
may be explained by the fact that all these patients were treated before the TMZ era 
(before 1994) and likely received RT alone.  
This study has shown that systematic combined morphologic and molecular 
characterization of tumor samples of patients enrolled in clinical trials is instrumental for 
validating and identifying new prognostic and predictive factors that will have an impact 
on clinical practice. This was an exploratory study requiring validation in an independent 
data-set of a homogenous patient population treated with combined chemo-
radiotherapy. The limited numbers of samples available for molecular analyses 
unfortunately reduced the power of the study, once more emphasizing the importance to 
collect sufficient tissues for all patients enrolled in clinical trials.  
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Figure Legends 
Fig. 1.  Examples of histology in two tumors diagnosed as glioblastoma with 
oligodendroglioma-like component. a Area showing diffuse highly cellular and 
monotonous growth of tumor cells with a dense chromatin pattern, perinuclear halo-
formation and chickenwire architecture of the microvasculature. b Highly cellular area 
showing rounded tumor cell nuclei with dense chromatin pattern and perinuclear halo-
formation. See Material and Methods for the definitions used in the present study for 
recognition of oligodendroglioma-like component in glioblastoma. Arrowheads in a: 
mitotic figures; arrowhead in b: florid microvascular proliferation. a, b: Hematoxylin-and-
Eosin staining, original magnification x200. 
 
Fig. 2. Patterns of genetic alterations, diagnosis and outcome. Patient data for 175 
cases with 3/6 genetic tests available were ordered according to overall survival (OS). 
Many features are rare, such as GBM subtypes, or genetic alterations like IDH1 
mutations. The visualization allows identification of patterns of genetic or clinical features 
that are enriched in either the short survival group or the long-term survival group. Gene 
amplification is represented in red (CDK4, MDM2, EGFR) and deletions in dark blue (co-
deletion of 1p/19q). Mutation of IDH1 is represented in red, and MGMT methylated in 
grey, unmethylated in black. OS in months: light green short survival group (≤ 9 months); 
green, intermediate survival group (>9 and <24 months), dark green, long-term survival 
group (≥24 months). Age <50 years is represented in grey, 50 to 60 years, dark gray, 
and >60 years in black; female, red, male blue. Diagnosis as GBM, pink; GBM-O, 
purple; Gliosarcoma, yellow; giant cell GBM (GC-GBM), orange; AOA, blue; other non-
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GBM diagnosis, green. Concordance of reviewers 3:0 for subtype (Con_subT) or 
diagnosis (Con_diagn) in dark blue; concordance 2:1, blue; diagnosis by Canadian 
central review, light blue. Diagnosis of non-GBM is indicated in black. No information, 
white for all criteria. The associated table below shows the respective numbers. 
EGFRvIII information was available for only 56 cases and is not included in the upper 
panel.  
 
Fig. 3. Gene expression based classification and GBM subtype.  
For 57 patients gene expression data, including for EGFRvIII, was available from frozen 
tumor tissue [21]. The tumor samples were classified according to the algorithm 
proposed by Verhaak et al. [36] into classic, mesenchymal, neural, and proneural GBM. 
The samples are ordered by the gene expression based classification, followed by 
diagnostic subtype, Gliosarcoma (GS), GBM-O, and GBM. The respective patho-genetic 
information and clinical information is the same as in Figure 1. The enrichment of 
specific pathogenetic alterations, such as IDH1 mutations in the proneural and EGFR 
amplification & EGFRvIII expression in the classical subtype, is in accordance with the 
report by Verhaak et al. [36]. Gene amplification is represented in red (CDK4, MDM2, 
EGFR) and deletions in dark blue (co-deletion of 1p/19q). EGFRvIII expression 
determined by qRT-PCR is depicted in yellow. Mutation of IDH1 is represented red, and 
MGMT methylated in grey, unmethylated in black. OS in months: light green short 
survival group (≤ 9 months); green, intermediate survival group (>9 and < 24 months), 
dark green, long-term survival group (≥24 months). Age <50 is represented in grey, 50 
to 60, dark grey, and >60 years in black; female, red, male blue. Diagnosis as GBM, 
pink; GBM-O, purple; Gliosarcoma (GS), yellow. Concordance of reviewers 3:0 for 
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subtype (Con_subT) or diagnosis (Con_diagn) in dark blue; concordance 2:1, blue; 
diagnosis by Canadian central review, light blue. No information, white for all criteria.  
 
Fig. 4. GBM-O have no better prognosis than all other GBM. 
Kaplan-Meier curves show the OS of GBM vs GBM-O in the RT arm (log-rank test 
p=0.136) (A) and the TMZ/RT→TMZ arm (p=0.814) (B).  
 
Fig. 5. Presence of pseudo-palisading necrosis is associated with a treatment effect. a 
The Kaplan-Meier curves visualize the overall outcome of the patients in presence or 
absence of pseudo-palisading necrosis (PPN). In presence of PPN there is a treatment 
effect (RT vs TMZ/RT→TMZ p=0.002), while in absence of PPN, no such difference is 
observed (RT versus TMZ/RT→TMZ, p=0.86). b Forest Plot and Peto’s test of 
interaction between PPN and treatment for OS in all confirmed GBM. Peto’s test was 
significant (p=0.03) indicating that treatment effects differ significantly as a function of 
PPN. 
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Table 1. Morphologic features of confirmed GBM and OS (N=339) 
 
 
Subsample Characteristics     
 
Treatment 
Total 
(N=339) 
 Prognostic value 
for  
Prognostic value 
for  
Prognostic value 
for  
RT 
(N=173) 
TMZ/RT 
(N=166) 
P-value 
Fisher 
Overal Survival  
P-value 
Overal Survival 
P-value 
Overal Survival 
P-value 
 N (%) N (%) N (%)  Pooled RT TMZ/RT 
Diagnosis                                                                                         
        Glioblastoma                             145 (83.8)        133 (80.1)       278 (82.0)       0.69    
        GBM-O   25 (14.5)          27 (16.3)          52 (15.3)           
        Giant cell glioblastoma              2 (1.2)            4 (2.4)            6 (1.8)             
        Gliosarcoma                                1 (0.6)            2 (1.2)            3 (0.9)             
GBM confirmed                                                                         
        GBM                   148 (85.5)        139 (83.7)        287 (84.7)       0.65 0.48 0.14 0.81 
        GBM-O                    25 (14.5)          27 (16.3)          52 (15.3)           
NECROSIS-Large ischaemic type                                                    
        No                    34 (19.7)          23 (13.9)          57 (16.8)       0.19 0.79 0.18 0.20 
        Yes                  139 (80.3)        143 (86.1)        282 (83.2)           
NECROSIS-Pseudopalisading                                                          
        No                    62 (35.8)          65 (39.2)         127 (37.5)       0.58 0.27 0.32 0.03 
        Yes                  111 (64.2)        101 (60.8)        212 (62.5)           
NECROSIS-Thrombosed vessels                                                    
        No                    27 (15.6)          28 (16.9)          55 (16.2)       0.77 0.48 0.99 0.40 
        Yes                  146 (84.4)        138 (83.1)        284 (83.8)           
Microvascular proliferation                                                   
        No                     2 (1.2)            4 (2.4)            6 (1.8)         0.44 0.80 0.98 0.92 
        Yes                  171 (98.8)        162 (97.6)        333 (98.2)           
Perivascular lymph                                                            
        No                   133 (76.9)        128 (77.1)        261 (77.0)       0.90 0.89 0.39 0.40 
        Yes                   38 (22.0)          35 (21.1)          73 (21.5)           
        Missing                2 (1.2)            3 (1.8)            5 (1.5)             
Oligodendroglioma-like 
component 
                                                  
        No                   129 (74.6)        120 (72.3)        249 (73.5)       0.80 0.24 0.29 0.52 
        Yes                   44 (25.4)          44 (26.5)          88 (26.0)           
        Missing                0 (0.0)            2 (1.2)            2 (0.6)             
Sarcomatous comp                                                              
        No                   167 (96.5)        157 (94.6)        324 (95.6)       0.57 0.15 0.16 0.34 
        Yes                    5 (2.9)            7 (4.2)           12 (3.5)            
        Missing                1 (0.6)            2 (1.2)            3 (0.9)             
Multinucleated giant cells                                                    
        No                   137 (79.2)        124 (74.7)        261 (77.0)       0.44 0.43 0.78 0.38 
        Yes                   36 (20.8)          40 (24.1)          76 (22.4)           
        Missing                0 (0.0)            2 (1.2)            2 (0.6)             
Gemistocytic cells                                                            
        No                   124 (71.7)        123 (74.1)        247 (72.9)       0.54 0.41 0.70 0.65 
        Yes                   49 (28.3)          41 (24.7)          90 (26.5)           
        Missing                0 (0.0)            2 (1.2)            2 (0.6)             
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Subsample Characteristics     
 
Treatment 
Total 
(N=339) 
 Prognostic value 
for  
Prognostic value 
for  
Prognostic value 
for  
RT 
(N=173) 
TMZ/RT 
(N=166) 
P-value 
Fisher 
Overal Survival  
P-value 
Overal Survival 
P-value 
Overal Survival 
P-value 
 N (%) N (%) N (%)  Pooled RT TMZ/RT 
Other Prominent patterns                                                      
        No                   157 (90.8)        141 (84.9)        298 (87.9)       0.21 0.82 0.13 0.75 
        Yes                   14 (8.1)           20 (12.0)          34 (10.0)           
        Missing                2 (1.2)            5 (3.0)            7 (2.1)             
MIB-1        
        Median                                      30.0            30.0            30.0            0.08
a
 0.13 0.65 0.24 
        Mean (SD)                                 32.72 (17.81)     36.40 (18.26)     34.53 (18.10)         
        Range                                        5.0 - 80.0        5.0 - 90.0        5.0 - 90.0            
        N obs                                         156             150             306                
aWilcoxon rank sum test 
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Table 2 Tumor genetics of GBM-O versus GBM     
 Confirmed GBM GBM-O GBM  
Overall Cases (%) (%) (%) p-valuea 
 in Central Review         
     
Alterations     
     
methMGMT 76/165 (46) 16/34 (47) 60/131 (46) 1.00 
     
IDH1 mut 9/130 (7)  6/32 (19)  3/98 (3) 0.007 
     
Co-del 1p/19q 2/137 (1)  1/31 (3) 1/106 (1) 0.4 
     
EGFR amp 70/131 (53)  22/31 (71)  48/100 (48) 0.038 
     
CDK4 amp 24/131 (18)  7/29 (24) 17/102 (17) 0.42 
     
MDM2 amp 13/131 (10)  4/30 (13) 9/101 (9) 0.49 
aFisher exact test     
 
 
 
 

NonGBM
Con_diagn
Con_subT
Diagnosis
Gender
Age
OS_months
MGMT_meth
IDH1mt
EGFRamp
1p/19q_codel
MDM2
CDK4
OS>9 and ≤24 monthsOS≤9 months OS>24 months
neg
amp
neg
codel
norm
mut
M
U
≤9 months
> 9 and ≤24 months
>24 months
≤50 years
> 50 and ≤60 years
>60 years
M
F
GS
GBM
GBM−O
GC−GBM
AOA
other
CA
2:1
3:0
GBM
nonGBM
GBM-O (52/354, 15%)        14/101 (14%)                                          29/189 (15%)                                  9/64 (14%)
nonGBM (15/354, 4%)          1/101  (1%)                                            5/189 (3%) 9/64 (14%)
O-comp (94/345, 27%)       20/101 (20%)                                          53/185 (29%) 21/59 (36%)
PPN (215/349, 62%)        60/102  (59%) 115/208 (55%) 39/62 (63%)
IDH1 mt (12/160, 8%)             1/38 (3%)                                               7/84 (8%)                                 4/38 (3 nonGBM)
Codel 1p/19q (2/168, 1%) 0/39 2/94 (2%) 0/94
EGFR amp (83/166, 50%) 22/40 (55%)                                          43/89 (48%)                                                18/37 (49%)
MGMT_m (103/226, 46%) 20/50 (40%)                                         47/129 (36%)                                               36/47 (77%)
CDK4 amp (27/164, 16%)       6/38 (16%) 16/90 (18%) 5/36 (14%) 
MDM2 amp (17/162, 11%)    3/38 (8%) 11/88 (13%) 3/26 (8%)
EGFRvIII (18/56, 30%) 7/18 (39%) 6/30 (17%) 5/13 (38%)
All Diagnosable Tumors in Central Review LN (n=354; including non-GBM)
Genecs, all Info Available (including non-GBM)
Samples
Con_diagn
Con_subT
Gender
Age
OS_months
1p/19q_codel
MDM2
CDK4
MGMT_meth
IDH1mt
EGFRvIII
EGFRamp
Diagnosis
Gene Exp Sub−T
Classical Mesenchymal Neural Proneural
Classical
Mesenchymal
Neural
Proneural
GS
GBM
GBM−O
neg
amp
neg
mut
norm
mut
M
U
neg
codel
≤9 months
>9 and ≤24 months
>24 months
≤50 years
> 50 and ≤60 years
>60 years
M
F
CA
2:1
3:0
Samples
a b 
(years) 
0 1 2 3 4 5 6 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
O N Number of patients at risk : GBM-O 
146 148 71 13 3 1 1 
24 25 15 5 1 1 0 
No 
Yes 
Overall Logrank test: p=0.136 
(years) 
0 1 2 3 4 5 6 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
O N Number of patients at risk : GBM-O 
130 139 82 33 14 5 3 
25 27 14 4 3 3 1 
No 
Yes 
Overall Logrank test: p=0.814 
P=0.002 
P=0.86 
(years) 
0 1 2 3 4 5 6 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
O N Number of patients at risk : Treatment and feature 
61 62 31 9 2 0 0 
109 111 55 9 2 2 1 
63 65 36 8 3 2 1 
92 101 60 29 14 6 3 
RT/no PPN 
RT/PPN 
TMZ-RT/no PPN 
TMZ-RT/PPN 
P=0.0015 (df=3) 
a 
b 
